UBS AM’s BioTelemetry, Inc. BEAT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-27,025
| Closed | -$1.95M | – | 2639 |
|
|
2020
Q4 | $1.95M | Sell |
27,025
-3,526
| -12% | -$185K | ﹤0.01% | 1697 |
|
|
2020
Q3 | $1.39M | Buy |
30,551
+2,171
| +8% | +$90.8K | ﹤0.01% | 1699 |
|
|
2020
Q2 | $1.28M | Sell |
28,380
-943
| -3% | -$42.3K | ﹤0.01% | 1700 |
|
|
2020
Q1 | $1.13M | Buy |
29,323
+1,131
| +4% | +$52.1K | ﹤0.01% | 1653 |
|
|
2019
Q4 | $1.31M | Sell |
28,192
-2,767
| -9% | -$120K | ﹤0.01% | 1783 |
|
|
2019
Q3 | $1.26M | Buy |
30,959
+3,178
| +11% | +$137K | ﹤0.01% | 1838 |
|
|
2019
Q2 | $1.34M | Buy |
27,781
+2,773
| +11% | +$146K | ﹤0.01% | 1771 |
|
|
2019
Q1 | $1.57M | Buy |
25,008
+1,325
| +6% | +$91K | ﹤0.01% | 1638 |
|
|
2018
Q4 | $1.41M | Buy |
23,683
+4,271
| +22% | +$256K | ﹤0.01% | 1584 |
|
|
2018
Q3 | $1.25M | Hold |
19,412
| – | – | ﹤0.01% | 1717 |
|
|
2018
Q2 | $874K | Sell |
19,412
-1,900
| -9% | -$75.8K | ﹤0.01% | 1864 |
|
|
2018
Q1 | $662K | Buy |
21,312
+13,812
| +184% | +$454K | ﹤0.01% | 1920 |
|
|
2017
Q4 | $224K | Sell |
7,500
-6,456
| -46% | -$187K | ﹤0.01% | 2247 |
|
|
2017
Q3 | $461K | Buy |
13,956
+7,731
| +124% | +$268K | ﹤0.01% | 1974 |
|
|
2017
Q2 | $208K | Buy |
+6,225
| New | +$186K | ﹤0.01% | 2200 |
|
Other funds holding BEAT
UBS AM's BEAT Position: Q1 2021 in Review
UBS AM sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 27,025 shares — an estimated $1.95M sold.
UBS AM first reported a position in BEAT in Q2 2017 and held it in 15 quarters. The position peaked at $1.95M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.
- UBS AM reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
- UBS AM sold 27,025 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.95M.
- UBS AM first reported a position in BioTelemetry, Inc. in Q2 2017 and held it in 15 quarters.
- UBS AM's BioTelemetry, Inc. position peaked at $1.95M in Q4 2020.
- 1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.
Based on UBS AM's 13F filing for Q1 2021, filed 14 May 2021.